Can-Fite Biopharma Ltd. (CANF) is an Israeli biopharmaceutical company that specializes in developing small molecule drugs for the treatment of autoimmune inflammatory diseases, cancer, and liver diseases. A random fact about Can-Fite is that one of its leading drug candidates, CF101 (Piclidenoson), is based on a unique mechanism of action involving the A3 adenosine receptor (A3AR). This receptor is overexpressed in inflammatory cells and cancer cells but not in normal cells, allowing Can-Fite’s drugs to target diseased cells specifically while minimizing damage to healthy cells. This approach has the potential to offer effective treatments with fewer side effects compared to traditional therapies.